Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 13/20 | 0.48 |
| ▸ | PPARA | Q07869 | 11/20 | 0.48 |
| ▸ | PPARD | Q03181 | 6/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5659310 | 0.91 | MAPK1 (0.43) | PPARGPPARAPPARDMAPK1CYP1A2 | |
| SCHEMBL5662474 | 0.90 | MAPK1 (0.45) | PPARGPPARAPPARDMAPK1CYP1A2 | |
| SCHEMBL5661825 | 0.90 | MAPK1 (0.45) | PPARGPPARAPPARDMAPK1CYP1A2 | |
| Arginine SCHEMBL5662107 | 0.87 | PPARG (0.38) | PPARGPPARAPPARDMAPK1CYP1A2 | |
| SCHEMBL14526265 | 0.84 | MAPK1 (0.45) | MAPK1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL5661240 | 0.84 | PPARG (0.50) | PPARGPPARAPPARD | |
| SCHEMBL14548460 | 0.83 | CDK4 (0.41) | MAPK1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL5662336 | 0.80 | MAPK1 (0.35) | MAPK1CYP1A2CYP3A4CYP2C19 | |
| Arginine SCHEMBL5659307 | 0.78 | MAPK1 (0.37) | PPARGPPARAMAPK1CYP1A2CYP3A4 | |
| SCHEMBL14548479 | 0.77 | CDK4 (0.43) | MAPK1CYP1A2CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070093476-A1 | Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES LIMITED (IN) | 2007-04-26 | — | — | US | disclosed |
| US-20070093476-A1 | Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES LIMITED (IN) | 2007-04-26 | — | — | US | disclosed |
| US-20070093476-A1 | Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES LIMITED (IN) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093476-A1 | Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them | GPR119, NR1H3, NR1H2 | PPARG 170/4885PPARA 251/4885PPARD 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.